4.4 Review

Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects

Journal

CURRENT MOLECULAR MEDICINE
Volume 9, Issue 6, Pages 673-682

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156652409788970670

Keywords

-

Funding

  1. Chiles Foundation
  2. Robert W. Franz
  3. Prostate Cancer Foundation
  4. Kuni Foundation
  5. Providence Medical Foundation
  6. Murdock Trust
  7. Chiles Visiting Fellow
  8. [R01 CA107243]
  9. [R01 CA102577]
  10. [R01 CA122701]
  11. [R01 CA109563]
  12. [R01 CA80964]
  13. [R01 CA119123]
  14. [R21 CA123864]
  15. [DAMD 17-03-1-0097]

Ask authors/readers for more resources

Since multiple lines of experimental and clinical data clearly identified regulatory T cells as an integral part of the immune response, these cells have become a major focus of investigation in tumor immunology. Regulatory T cells are in place to dampen ongoing immune responses and to prevent autoimmunity, but they also have profound effects in blocking therapeutic anti-tumor activity. Therefore regulatory T cells are seen as a major hurdle that must be overcome in order for cancer immunotherapy to reach its therapeutic potential. Regulatory T cells are heterogeneous with sub-populations that exhibit distinct functional features. Here we will review the individual sub-populations in regards to their mode of action and their potential impact on blocking anti-tumor immunity. Approaches to measure function and frequency of regulatory T cells in model systems and clinical trails will be discussed. Finally, we will describe possible ways to interfere with regulatory T cell-mediated immune suppression with the focus on recent pre-clinical and clinical findings.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available